Learn About Developments Surrounding the Importation of Prescription Drugs From Canada into the U.S.FDLI's Audioconference on: Importation of Prescription Drugs from Canada, Part II: What's Next?
WASHINGTON, Nov. 24, 2003 - Tuesday, December 16, 2003 1:00 - 3:00 p.m. (EDT)
Moderator Douglas B. Farquhar, Principal, Hyman, Phelps & McNamara, P.C.
Speakers: Gordon S. Jepson, Partner, Deeth Williams Wall LLP (Toronto) Oliver Kim, Office of Senator Debbie Stabinow (D-MI) (invited) Scott M. Lassman, Assistant General Counsel, Pharmaceutical Research and Manufacturers of America Thomas J. McGinnis, R.Ph., Director of Pharmacy Affairs, Office of the Commissioner, Food & Drug Administration (invited) Healthcare Distribution Management Association Speaker
A federal district court recently issued a decision shutting down, at FDA's request, a U.S. company that was facilitating the importation of prescription drugs from Canada. Some pharmaceutical manufacturers have been scrambling to identify technologies and techniques that will enable them to prevent or detect prescription drugs being imported into the U.S. Many pharmaceutical manufacturers are hopeful that FDA and the Canadian government will cooperate to stop pharmacists exporting drugs from Canada.
FDA's Commissioner recently met with Canadian officials to try to secure cooperation in stemming the flow of prescription drugs from Canada into the United States, although the Canadian government said that no Canadian laws appeared to have been violated by the exports. What will FDA do about cities, states, and health plans that are encouraging employees to import drugs from Canada?
Legislation has been proposed that would legalize the importation of prescription drugs from Canada, even if FDA objects. And Canadian pharmacies are complaining of looming drug shortages because some manufacturers are reducing shipments of prescription drugs into Canada, to try to cut off the source of prescription drugs that can be exported into the United States.
This audioconference will examine the developments surrounding the importation of prescription drugs from Canada into the United States. Even if you participated in the FDLI audio conference last April on this topic, you need to be acquainted with the important new developments in case law, technology, and legislation addressing this issue.
Discussion Topics Include:
* The chances of legislation being enacted that would permit blanket imports of prescription drugs from Canada, even when the Secretary of the Department of Health and Human Services does not certify there are no safety issues.
* Why the court deciding United States v. Rx Depot ruled that United States companies may not assist customers who want to order drugs from Canadian pharmacies, what the chances are for an appeal of this decision, and whether other courts would likely decide the issue differently.
* What the industry is doing to address illicit product entering the domestic supply system
* What efforts drug manufacturers can take to detect illegal importation of their drugs into the United States.
* What efforts FDA, Canada and state governments can be expected to take to enforce legal prohibitions on importation of prescription drugs into the United States.
This audioconference is perfect for lawyers and lobbyists who work for or represent drug companies or wholesalers with U.S. sales of prescription drugs, sales directors and other executives of drug companies with U.S. sales of prescription drugs, decision-makers at any company that runs or is considering running a consumer-oriented website or storefront offering drugs from Canadian pharmacies, and representatives of insurance or other companies who help consumers to obtain drugs from Canada. Also anyone interested in legislation strengthening or nullifying the prohibition on importing most prescription drugs are encouraged to attend.
Complete audioconference and registration information is available at http://www.fdli.org/conf/import02/.
Register Today! Please call (800) 956-6293 or (202) 371-1420 or visit http://www.fdli.org/conf/import02/registration.phtml
(Registration must be received by 10:00 am EDT on Tuesday, December 16.)
AUDIOCONFERENCE ONLY $299 Member, Government, Academic, 501(c) (3) organizations $499 Non-member
AUDIOCONFERENCE & AUDIOTAPE $374 Member, Government, Academic, 501(c) (3) organizations $574 Non-member
AUDIOTAPE WITHOUT REGISTRATION $175 Member, Government, Academic, 501(c) (3) organizations $225 Non-member
Get answers to your questions either by calling in during the audioconference or by submitting them anonymously by e-mail to email@example.com before the audioconference.
Posted: November 2003